WORCESTER, Mass.--(BUSINESS WIRE)--RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced that Anastasia Khvorova, Ph.D., has joined the Company in the newly created position of Chief Scientific Officer (CSO). Dr. Khvorova previously served as CSO at Dharmacon, Inc. (now a Thermo Fisher Scientific company), one of the world’s foremost developers and suppliers of RNAi compounds.
